🧬 Hemas Surgicals & Credence Genomics Partner to Launch AI-Powered Diagnostics in SL & Maldives

• Strategic Healthcare Expansion: Hemas Surgicals & Diagnostics has signed a agreement to serve as the authorised distributor for Singapore-based Credence Genomics Holdings, introducing advanced AI-driven genomic diagnostic solutions to Sri Lanka and the Maldives. • Advanced Technology Stack: The molecular diagnostic platform combines artificial intelligence with genomic sequencing to identify infectious diseases faster and assess antimicrobial resistance. It operates on two proprietary systems—AIoS® (Artificial Intelligence on Sequencing) and MMR™ (Machine Modelled Resistance). • Product Portfolio & Capabilities: • Bactfast®: Detects 22,000+ bacteria. • Fungifast®: Covers 6,000+ fungi. • Virfast®: Analyzes 9,000+ DNA and RNA viruses. • dABST®: Predictive antimicrobial susceptibility testing to forecast antibiotic resistance. • Market Availability: The solutions will be distributed across local hospitals, laboratories, and healthcare institutions following mandatory regulatory approvals.